UnitedHealth Group appoints Stephen J. Hemsley as CEO and suspends its 2025 financial outlook due to rising Medicare Advantage medical costs, with growth expected to resume in 2026.
CMS issued final rules and updates for Medicare Advantage and Part D programs for 2026, including Inflation Reduction Act implementations and inpatient care protections.
President Trump signs an executive order setting a 30-day deadline for drugmakers to lower prescription drug prices in the U.S. or face new federal limits tied to international prices.
President Trump announces an executive order aiming to reduce U.S. prescription drug prices by 30-80% through a 'Most Favored Nation' pricing policy affecting healthcare and insurance markets.
Democrats call on GOP leaders to stop Medicaid cuts and focus on Medicare Advantage upcoding to reduce $50 billion in federal overpayments and protect healthcare coverage.
UnitedHealth Group faces a securities class action lawsuit after slashing 2025 earnings guidance and reporting Q1 losses, raising issues on Medicare Advantage utilization and corporate disclosures.
The DOJ sued SelectQuote and major insurers over Medicare Advantage plan kickbacks, leading to a 19% stock drop. This case highlights key compliance risks in broker compensation and Medicare Advantage enrollment.
Levi & Korsinsky LLP has commenced an investigation into CVS Health following DOJ allegations of illegal kickbacks related to Medicare Advantage plan enrollments, highlighting increased regulatory focus on insurance brokerage compliance.
Arizona mandates independent medical director reviews for health insurer claims denials and prior authorizations based on medical necessity, effective June 2026.
The Trump administration plans to reintroduce a 'most favored nation' drug pricing model for Medicare, aiming to align U.S. drug prices with lower international rates. This strategy faces industry opposition but could complement existing Medicare drug price negotiations to reduce costs.
